🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

'Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem

Published 06/05/2024, 04:50
Updated 06/05/2024, 06:10
© Reuters.  'Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem
NVO
-

Benzinga - by Ananya Gairola, Benzinga Staff Writer.

Tesla and SpaceX CEO Elon Musk has sparked a conversation about childhood obesity and potential solutions after giving his seal of approval for Novo Nordisk‘s (NYSE:NVO) Ozempic, a GLP-1 agonist primarily prescribed to manage Type 2 diabetes.

What Happened: On Sunday, Musk responded to a post on X about childhood obesity in the U.S. and Japan. The post by Calley Means, co-founder of health startup Truemed, suggested five policies to address the issue, including banning TV pharma ads and reforming agriculture subsidies.

It was re-shared by billionaire investor Bill Ackman, who tagged Joe Biden, Donald Trump, and Robert Kennedy Jr. — the three major presidential candidates for the 2024 elections, saying, “This is great advice.”

Musk responded to Ackman’s post, saying, “Ozempic ftw,” indicating his support for the drug.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.